Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries flag tag at the N-terminus and polyhistidine tag at the C-terminus.
The protein has a calculated MW of 37.9 kDa.
>85% as determined by SDS-PAGE.
This product is not suitable for cell based experiments due to cytotoxicity of DDM.
DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove DDM and CHS.
DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Immobilized Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) at 1 μg/mL (100 μL/well) can bind Anti-GPRC5D Antibody, Human IgG4 with a linear range of 0.5-16 ng/mL (QC tested).
Immobilized Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) at 1 μg/mL, add Glofitamab and then add Biotinylated Human CD3E&CD3G Heterodimer Protein, His,Avitag&Tag Free (Cat. No. CDG-H82W3) at 5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).
Anti-GPRC5D Antibody, Human IgG4 captured on Protein A Chip can bind Human GPRC5D Full Length Protein, Flag,His Tag (Cat. No. GPD-H52D5) with an affinity constant of 57.7 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | Zhejiang University | Multiple Myeloma | Details |
MCARH-109 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details | |
RO-7425781 | RO-7425781 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
CAR-GPRC5D | CAR-GPRC5D | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
Autologous anti-BCMA/GPRC5D CAR-T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
Ori-CAR-017 | OriCAR-017; Ori-CAR-017 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Multiple Myeloma | Details |
Talquetamab | JNJ-7564; JNJ-64407564 | Phase 3 Clinical | Janssen Global Services Llc, Genmab A/S | Hematologic Neoplasms; Multiple Myeloma | Details |
LM-305 | LM-305 | Phase 1 Clinical | LaNova Medicines Ltd | Multiple Myeloma | Details |
RG-6234 | RG-6234 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Multiple Myeloma | Details |
This web search service is supported by Google Inc.